Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Verve Therapeutics (VERV – Research Report), with a price target of $55.00.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors that indicate a positive outlook for Verve Therapeutics. His assessment is informed by the company’s progress with its ongoing VERVE-101 Heart-1 study and its upcoming Heart-2 study for VERVE-102. The company’s proactive approach to enrolling participants and activating study sites, particularly in the United States, enhances its potential for timely data updates, slated for the second half of 2024. Furthermore, the potential for VERVE-102 to advance into a more extensive Phase II program in 2025, based on its promising product profile, contributes to the positive rating.
The potential of VERVE-102 lies in its improved delivery mechanism which utilizes a GalNAc-directed approach, offering versatility for patients with hepatic LDLR expression deficiencies. This differentiator could provide a competitive clinical advantage. Additionally, the fact that VERVE-102 employs Novartis’ ionizable lipid, which has not shown significant post-treatment transaminase elevations in clinical use, as opposed to VERVE-101’s lipid, may appeal to both patients and prescribers concerned about treatment side effects. These strategic and clinical advancements position Verve Therapeutics favorably in the market, underpinning Jubinville’s Buy recommendation.
In another report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $35.00 price target.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Verve Therapeutics (VERV) Company Description:
Verve Therapeutics Inc is a genetic medicines company pioneering the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Its initial programs focus on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. The company is developing these gene-editing treatments for patients with familial hypercholesterolemia, a genetic disease that causes life-long severely elevated blood cholesterol.
Read More on VERV:
- Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
- Verve Therapeutics reports Q4 EPS (69c), consensus (82c)
- Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
